The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy

Further Publications

The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression

Eur J Cancer

Saal J, Eckstein M, Ritter M, Brossart P, Hölzel M, Grünwald V, Klümper N

doi: 10.1016/j.ejca.2024.115163

ASH 2025

Multiple Myeloma (MM)

KarMMa-3: Ide-cel demonstrates clinical benefit in patients aged 70 years and older with RRMM

EHA 2025

Multiple Myeloma (MM)

PREDATOR-MRD: Early daratumumab delays clinical progression in patients with MM experiencing MRD relapse

CHICAGO 2025

Genitourinary Cancer

KEYNOTE-564: Long-term clinical benefit with adjuvant pembrolizumab in patients with ccRCC

Breast Cancer

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

J Natl Cancer Inst

Johansson A, Dar H, Nordenskjöld A, Perez-Tenorio G, Tobin NP, Yau C, Benz CC, Esserman LJ, van 't Veer LJ, Nordenskjöld B, Stål O, Fornander T, Lindström LS

doi: 10.1093/jnci/djae268

Lung, Respiratory and Thoracic Cancer

Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS

Eur J Cancer

Gobbini E, Langlais A, Missy P, Chanoine S, Besse B, Souquet PJ, Barlesi F, Audigier-Valette C, Métivier AC, Monnet I, Hureaux J, Jeannin G, Cadranel J, Lagrange A, Tran Q, Morin F, Molinier O, Westeel V, Girard N, Moro-Sibilot D

doi: 10.1016/j.ejca.2025.115560

Gastrointestinal Cancer

Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes

Eur J Cancer

Fortuny M, García-Calonge M, Arrabal Ó, Sanduzzi-Zamparelli M, Castaño-García A, Cascos E, Mesa A, Piedra-Cerezal AM, Llarch N, Iserte G, Campos M, González M, Marsal A, Lorca R, Rodríguez M, Torres F, Varela M, Reig M

doi: 10.1016/j.ejca.2025.115404

Head and Neck Cancer

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

Exp Hematol Oncol

Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach N

doi: 10.1186/s40164-025-00703-x

Lung, Respiratory and Thoracic Cancer

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases

Lung Cancer

Huijs JWJ, Sadowska AM, Degens JHRJ, Steendam CMJ, Bensch F, Hijmering-Kappelle LBM, de Schrevel TMT, van Geffen WH, Youssef-El Soud M, Steens MMH, Pitz C, De Ruysscher DKM, Hendriks LEL

doi: 10.1016/j.lungcan.2025.108745

Related content

The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression

KarMMa-3: Ide-cel demonstrates clinical benefit in patients aged 70 years and older with RRMM

PREDATOR-MRD: Early daratumumab delays clinical progression in patients with MM experiencing MRD relapse

KEYNOTE-564: Long-term clinical benefit with adjuvant pembrolizumab in patients with ccRCC

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS

Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases